(NVST) Envista Holdings - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 3.951m USD | Total Return: 28.4% in 12m

Dental Implants, Orthodontics, Imaging Systems, Consumables
Total Rating 45
Safety 65
Buy Signal -0.17
Medical Instruments & Supplies
Industry Rotation: +2.0
Market Cap: 3.95B
Avg Turnover: 68.9M
Risk 3d forecast
Volatility42.2%
VaR 5th Pctl6.94%
VaR vs Median-0.03%
Reward TTM
Sharpe Ratio0.71
Rel. Str. IBD45.9
Rel. Str. Peer Group66.9
Character TTM
Beta1.733
Beta Downside1.950
Hurst Exponent0.490
Drawdowns 3y
Max DD58.70%
CAGR/Max DD-0.23
CAGR/Mean DD-0.35
EPS (Earnings per Share) EPS (Earnings per Share) of NVST over the last years for every Quarter: "2021-03": 0.54, "2021-06": 0.53, "2021-09": 0.45, "2021-12": 0.46, "2022-03": 0.47, "2022-06": 0.48, "2022-09": 0.47, "2022-12": 0.52, "2023-03": 0.38, "2023-06": 0.43, "2023-09": 0.43, "2023-12": 0.29, "2024-03": 0.26, "2024-06": 0.11, "2024-09": 0.12, "2024-12": 0.24, "2025-03": 0.1, "2025-06": 0.26, "2025-09": 0.32, "2025-12": 0.38, "2026-03": 0.23,
EPS CAGR: -17.81%
EPS Trend: -51.6%
Last SUE: 0.25
Qual. Beats: 0
Revenue Revenue of NVST over the last years for every Quarter: 2021-03: 612.6, 2021-06: 637.2, 2021-09: 607.3, 2021-12: 651.8, 2022-03: 631.4, 2022-06: 645.8, 2022-09: 631.1, 2022-12: 660.8, 2023-03: 627.2, 2023-06: 662.4, 2023-09: 631.3, 2023-12: 645.6, 2024-03: 623.6, 2024-06: 633.1, 2024-09: 601, 2024-12: 652.9, 2025-03: 616.9, 2025-06: 682.1, 2025-09: 669.9, 2025-12: 750.6, 2026-03: 705.5,
Rev. CAGR: 2.39%
Rev. Trend: 50.1%
Last SUE: 0.91
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: NVST Envista Holdings

Envista Holdings Corporation (NYSE: NVST) is a global manufacturer and distributor of dental products, operating through two primary segments: Specialty Products & Technologies and Equipment & Consumables. The company’s portfolio includes dental implants, orthodontic systems, clear aligners, and digital imaging software, marketed under brands such as Nobel Biocare, Ormco, and Dexis. Headquartered in Brea, California, the firm serves a diverse customer base ranging from general dentists to specialized oral surgeons and hospitals.

The dental equipment sector is characterized by a high degree of brand loyalty and significant switching costs, as practitioners often standardize their workflows around specific imaging software and clinical tools. Envista’s business model relies on a mix of high-margin specialized consumables and capital equipment, benefiting from the long-term growth in global demand for aesthetic dentistry and advanced restorative procedures.

Consulting ValueRay can provide further clarity on how these segments influence the companys valuation.

Headlines to Watch Out For
  • China volume-based procurement policies pressure dental implant margins and revenue
  • Spark clear aligner adoption drives specialty segment growth and market share
  • High interest rates reduce consumer demand for elective dental procedures
  • Operational restructuring and lean initiatives impact long-term EBITDA margin expansion
  • Dental equipment sales sensitivity to high capital expenditure costs for clinics
Piotroski VR‑10 (Strict) 6.5
Net Income: 67.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.95 > 1.0
NWC/Revenue: 40.33% < 20% (prev 39.00%; Δ 1.33% < -1%)
CFO/TA 0.05 > 3% & CFO 272.1m > Net Income 67.7m
Net Debt (506.4m) to EBITDA (342.0m): 1.48 < 3
Current Ratio: 2.44 > 1.5 & < 3
Outstanding Shares: last quarter (166.4m) vs 12m ago -4.15% < -2%
Gross Margin: 55.14% > 18% (prev 0.54%; Δ 5.46k% > 0.5%)
Asset Turnover: 50.85% > 50% (prev 45.81%; Δ 5.05% > 0%)
Interest Coverage Ratio: 5.52 > 6 (EBITDA TTM 342.0m / Interest Expense TTM 34.7m)
Altman Z'' 1.10
A: 0.20 (Total Current Assets 1.92b - Total Current Liabilities 786.6m) / Total Assets 5.58b
B: -0.07 (Retained Earnings -401.7m / Total Assets 5.58b)
C: 0.03 (EBIT TTM 191.4m / Avg Total Assets 5.52b)
D: -0.22 (Book Value of Equity -543.0m / Total Liabilities 2.50b)
Altman-Z'' Score: 1.10 = BB
Beneish M -3.01
DSRI: 0.99 (Receivables 436.6m/393.1m, Revenue 2.81b/2.50b)
GMI: 0.98 (GM 55.14% / 54.18%)
AQI: 0.99 (AQ_t 0.58 / AQ_t-1 0.59)
SGI: 1.12 (Revenue 2.81b / 2.50b)
TATA: -0.04 (NI 67.7m - CFO 272.1m) / TA 5.58b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA
What is the price of NVST shares? As of May 17, 2026, the stock is trading at USD 23.22 with a total of 3,850,435 shares traded.
Over the past week, the price has changed by -4.21%, over one month by -14.10%, over three months by -17.28% and over the past year by +28.36%.
Is NVST a buy, sell or hold? Envista Holdings has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold NVST.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the NVST price?
Analysts Target Price 29.9 28.6%
Envista Holdings (NVST) - Fundamental Data Overview as of 14 May 2026
P/E Trailing = 59.2195
P/E Forward = 20.3252
P/S = 1.407
P/B = 1.2809
Revenue TTM = 2.81b USD
EBIT TTM = 191.4m USD
EBITDA TTM = 342.0m USD
Long Term Debt = 1.44b USD (from longTermDebt, last quarter)
Short Term Debt = 38.7m USD (from shortTermDebt, last quarter)
Debt = 1.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 506.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.46b USD (3.95b + Debt 1.59b - CCE 1.08b)
Interest Coverage Ratio = 5.52 (Ebit TTM 191.4m / Interest Expense TTM 34.7m)
EV/FCF = 20.24x (Enterprise Value 4.46b / FCF TTM 220.2m)
FCF Yield = 4.94% (FCF TTM 220.2m / Enterprise Value 4.46b)
FCF Margin = 7.84% (FCF TTM 220.2m / Revenue TTM 2.81b)
Net Margin = 2.41% (Net Income TTM 67.7m / Revenue TTM 2.81b)
Gross Margin = 55.14% ((Revenue TTM 2.81b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 55.29% (prev 55.04%)
Tobins Q-Ratio = 0.80 (Enterprise Value 4.46b / Total Assets 5.58b)
Interest Expense / Debt = 0.47% (Interest Expense 7.40m / Debt 1.59b)
Taxrate = 25.86% (13.5m / 52.2m)
NOPAT = 141.9m (EBIT 191.4m * (1 - 25.86%))
Current Ratio = 2.44 (Total Current Assets 1.92b / Total Current Liabilities 786.6m)
Debt / Equity = 0.52 (Debt 1.59b / totalStockholderEquity, last quarter 3.08b)
Debt / EBITDA = 1.48 (Net Debt 506.4m / EBITDA 342.0m)
Debt / FCF = 2.30 (Net Debt 506.4m / FCF TTM 220.2m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.23% (Net Income 67.7m / Total Assets 5.58b)
RoE = 2.18% (Net Income TTM 67.7m / Total Stockholder Equity 3.10b)
RoCE = 4.21% (EBIT 191.4m / Capital Employed (Equity 3.10b + L.T.Debt 1.44b))
RoIC = 3.12% (NOPAT 141.9m / Invested Capital 4.55b)
WACC = 8.71% (E(3.95b)/V(5.54b) * Re(12.08%) + D(1.59b)/V(5.54b) * Rd(0.47%) * (1-Tc(0.26)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -1.38%
[DCF] Terminal Value 77.60% ; FCFF base≈239.2m ; Y1≈268.3m ; Y5≈358.0m
[DCF] Fair Price = 30.54 (EV 5.48b - Net Debt 506.4m = Equity 4.97b / Shares 162.7m; r=8.71% [WACC]; 5y FCF grow 14.07% → 3.0% )
EPS Correlation: -51.61 | EPS CAGR: -17.81% | SUE: 0.25 | # QB: 0
Revenue Correlation: 50.09 | Revenue CAGR: 2.39% | SUE: 0.91 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+3.79% | Revisions=+29% | Analysts=14
EPS next Quarter (2026-09-30): EPS=0.34 | Chg30d=-5.12% | Revisions=-69% | Analysts=14
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=+1.36% | Revisions=+71% | GrowthEPS=+20.1% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=1.57 | Chg30d=+0.65% | Revisions=+20% | GrowthEPS=+9.8% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +71%